Department of Medicine, Duke University, Durham, NC, USA.
Osteoarthritis Cartilage. 2010 Jun;18(6):742-5. doi: 10.1016/j.joca.2010.02.014. Epub 2010 Mar 4.
Osteoarthritis (OA) biomarkers that can measure and predict the full spectrum of disease progression and outcomes are needed, but few, if any, such biomarkers have been validated for this purpose. The Osteoarthritis Research Society International (OARSI) has organized an OA Biomarkers Global Initiative. As a part of this Initiative, three workshops have been planned to occur over the next 4 years to focus on identifying and removing obstacles to progress in the field and planning the way forward. In addition to OARSI, the National Institute of Arthritis, Musculoskeletal, and Skin Disease, the Arthritis Foundation, the Orthopaedic Research Society, and the American Orthopaedic Sports Medicine Society cosponsored the first meeting April 23-24, 2009. Organizers brought together thought and research leaders in the field, young investigators, biomarkers researchers with insights from other fields, clinical investigators with a responsibility for OA sample and resource management, funding agencies, and commercial entities with an interest in the commercial propagation as well as the application of markers in OA.
需要能够衡量和预测疾病进展和结局全谱的骨关节炎 (OA) 生物标志物,但很少有此类生物标志物经过验证可用于此目的。国际骨关节炎研究学会 (OARSI) 已成立骨关节炎生物标志物全球倡议。作为该倡议的一部分,计划在未来 4 年内举办三个研讨会,重点是确定和消除该领域进展的障碍,并规划前进的道路。除 OARSI 外,美国国立关节炎、肌肉骨骼和皮肤病研究所、关节炎基金会、矫形研究学会和美国矫形运动医学学会也共同赞助了 2009 年 4 月 23 日至 24 日的第一次会议。组织者汇集了该领域的思想和研究领导者、年轻研究人员、具有其他领域见解的生物标志物研究人员、负责 OA 样本和资源管理的临床研究人员、资助机构以及对生物标志物在 OA 中的商业应用和推广有兴趣的商业实体。